This product, based on the synergism between both types of IFNs, was registered for basal cell carcinomas where was demonstrated the clinical superiority of HeberFERON (IFN α/γ) over individual IFN treatments [6]. The gene discussed is IFNA1; the disease is basal cell carcinoma.